Drugs & Aging

, Volume 20, Issue 10, pp 723–736 | Cite as

Methotrexate Intolerance in Elderly Patients with Rheumatoid Arthritis

What Are the Alternatives?
Therapy In Practice

Abstract

Rheumatoid arthritis (RA) in the elderly may be mild or severe, with features that are similar to those seen in younger patients. As such, the treatment regimen in the elderly is almost the same as in younger patients. Methotrexate is the most popular disease-modifying antirheumatic drug (DMARD) for the treatment of RA in the US and Europe. It has excellent efficacy and an acceptable toxicity profile. However, a number of patients do not tolerate methotrexate and an alternative DMARD should be chosen.

In the elderly, choice of an alternative DMARD should be made after careful consideration of several age-related factors including concomitant diseases, existing medication, drug compliance, and altered age-related physiology and pharmacokinetics.

In elderly patients with RA who are unable to tolerate methotrexate, the alternatives are hydroxychloroquine or sulfasalazine for mild-to-moderate disease and cyclosporin or leflunomide for severe disease, given in combination with low-dose oral corticosteroids. This is primarily due to their efficacy combined with a relatively low toxicity profile compared with other DMARDs, such as gold compounds, penicillamine, azathioprine and alkylating agents. Where the above DMARDs are contraindicated, anticytokine therapy should be considered.

The therapy of RA is a dynamic process and requires a delicate balance of benefits and risks. Experience and familiarity with the currently available agents, and knowledge of the nature of the disease are necessary in order to make better therapeutic decisions.

Keywords

Rheumatoid Arthritis Methotrexate Cyclosporin Rheumatoid Arthritis Patient Sulfasalazine 

Notes

Acknowledgements

The author would like to thank Mrs Eleni Horti for her secretarial assistance. No sources of funding were used to assist in the preparation of this manuscript. The author has no conflicts of interest that are directly relevant to the content of this manuscript.

References

  1. 1.
    Harris Jr ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990 May 3; 332(18): 1277–89Google Scholar
  2. 2.
    Odeh M. New insights into the pathogenesis and treatment of rheumatoid arthritis. Clin Immunol Immunopathol 1997 May; 83(2): 103–16PubMedCrossRefGoogle Scholar
  3. 3.
    Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001 Mar 22; 344(12): 907–16PubMedCrossRefGoogle Scholar
  4. 4.
    Smyth CJ. Therapy of rheumatoid arthritis: a pyramidal plan. Postgrad Med 1972 May; 51(6): 31–9PubMedGoogle Scholar
  5. 5.
    Scott DL, Symmons DP, Coulton BL, et al. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1987 May 16; I(8542): 1108–11CrossRefGoogle Scholar
  6. 6.
    Conaghan PG, Lehmann T, Brooks P. Disease-modifying antirheumatic drugs. Curr Opin Rheumatol 1997 May; 9(3): 183–90PubMedCrossRefGoogle Scholar
  7. 7.
    Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis: The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995 Jul 20; 333(3): 142–6PubMedCrossRefGoogle Scholar
  8. 8.
    Drosos AA. Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy. Drugs 2002; 62(6): 891–907PubMedCrossRefGoogle Scholar
  9. 9.
    van Schaardenburg D, Breedveld FC. Elderly-onset rheumatoid arthritis. Semin Arthritis Rheum 1994 Jun; 23(6): 367–78PubMedCrossRefGoogle Scholar
  10. 10.
    Nesher G, Moore TL, Zuckner J. Rheumatoid arthritis in the elderly. J Am Geriatr Soc 1991 Mar; 39(3): 284–94PubMedGoogle Scholar
  11. 11.
    Nesher G, Moore TL. Rheumatoid arthritis in the aged: incidence and optimal management. Drugs Aging 1993 Nov-Dec; 3(6): 487–501PubMedCrossRefGoogle Scholar
  12. 12.
    Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. Rheumatol Int 2003; 23: 70–4PubMedGoogle Scholar
  13. 13.
    Nesher G, Moore TL. Clinical presentation and treatment of arthritis in the aged. Clin Geriatr Med 1994 Nov; 10(4): 659–75PubMedGoogle Scholar
  14. 14.
    O’Callaghan JW, Brooks PM. Disease-modifying agents and immunosuppressive drugs in the elderly. Clin Rheum Dis 1986 Apr; 12(1): 275–89PubMedGoogle Scholar
  15. 15.
    Morgan J, Furst DE. Implications of drug therapy in the elderly. Clin Rheum Dis 1986 Apr; 12(1): 227–44PubMedGoogle Scholar
  16. 16.
    Gardner G, Furst DE. Disease-modifying antirheumatic drugs: potential effects in older patients. Drugs Aging 1995 Dec; 7(6): 420–37PubMedCrossRefGoogle Scholar
  17. 17.
    Nesher G, Moore TL. Recommendations for drug therapy of rheumatoid arthritis in elderly patients. Clin Immunother 1996; 5: 341–50CrossRefGoogle Scholar
  18. 18.
    Gubner R, August S, Ginsberg V. Therapeutic suppression of tissue reactivity: II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 1951; 221: 176–82PubMedCrossRefGoogle Scholar
  19. 19.
    Smith Jr JM, Cosulich DB, Hultquist ME, et al. The chemistry of certain pteroplutamic acid antagonists. Trans N Y Acad Sci 1948; 10: 82–3CrossRefGoogle Scholar
  20. 20.
    Herman RA, Veng Pedersen P, Hoffman J, et al. Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients. J Pharm Sci 1989 Feb; 78(2): 165–71PubMedCrossRefGoogle Scholar
  21. 21.
    Auvinet B, Jarrier I, Le Levier F, et al. Compared bioavailability of methotrexate administered orally or intramuscularly in rheumatoid arthritis [in French] [letter]. Presse Med 1992 May 2–9; 21(17): 822PubMedGoogle Scholar
  22. 22.
    Oguey D, Kolliker F, Gerber NJ, et al. Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1992 Jun; 35(6): 611–4PubMedCrossRefGoogle Scholar
  23. 23.
    Sinnett MJ, Groff GB, Raddatz DA, et al. Methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1989 Jun; 16(6): 745–8PubMedGoogle Scholar
  24. 24.
    Nuernberg B, Koehnke R, Solsky M, et al. Biliary elimination of low-dose methotrexate in humans. Arthritis Rheum 1990 Jun; 33(6): 898–902PubMedCrossRefGoogle Scholar
  25. 25.
    Evans ME, Ehristensen ML. Drug interactions with methotrexate. J Rheumatol 1985; 12Suppl. 12: 15–20Google Scholar
  26. 26.
    Cronstein BN. Molecular mechanism of methotrexate action in inflammation. Inflammation 1992 Oct; 16(5): 411–23PubMedCrossRefGoogle Scholar
  27. 27.
    Kremer J. The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 1994 Jan; 21(1): 1–5PubMedGoogle Scholar
  28. 28.
    Cronstein BN. Molecular therapeutics: methotrexate and its mechanism of action. Arthritis Rheum 1996 Dec; 39(12): 1951–60PubMedCrossRefGoogle Scholar
  29. 29.
    Olsen NJ, Callahan LF, Pincus T. Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1987 May; 30(5): 481–8PubMedCrossRefGoogle Scholar
  30. 30.
    Segal R, Mozes E, Yaron M, et al. The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 1989 Apr; 32(4): 370–7PubMedCrossRefGoogle Scholar
  31. 31.
    Wilke WS, Calabrese LH, Scherbel AL. Methotrexate in the treatment of rheumatoid arthritis: pilot study. Cleve Clin Q 1980 Winter; 47(4): 305–9PubMedGoogle Scholar
  32. 32.
    Willkens RF, Watson MA, Paxson CS. Low dose pulse methotrexate therapy in rheumatoid arthritis. J Rheumatol 1980 Jul-Aug; 7(4): 501–5PubMedGoogle Scholar
  33. 33.
    Thompson RN, Watts C, Edelman J, et al. A controlled two-centre trial of parenteral methotrexate therapy for refractory rheumatoid arthritis. J Rheumatol 1984 Dec; 11(6): 760–3PubMedGoogle Scholar
  34. 34.
    Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 1985 Mar 28; 312(13): 818–22PubMedCrossRefGoogle Scholar
  35. 35.
    Williams HJ, Willkens RF, Samuelson Jr CO, et al. Comparison of low-dose oral pulse methotrexate and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1985 Jul; 28(7): 721–30PubMedCrossRefGoogle Scholar
  36. 36.
    Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis. Arthritis Rheum 1986 Jul; 29(7): 822–31PubMedCrossRefGoogle Scholar
  37. 37.
    Weinblatt ME, Trentham DE, Fraser PA. Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 1988 Feb; 31(2): 167–75PubMedCrossRefGoogle Scholar
  38. 38.
    Drosos AA, Psychos D, Andonopoulos AP, et al. Methotrexate therapy in rheumatoid arthritis: a two year prospective follow-up. Clin Rheumatol 1990 Sep; 9(3): 333–41PubMedCrossRefGoogle Scholar
  39. 39.
    Kremer JM, Phelps CT. Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Arthritis Rheum 1992; 35: 138–45PubMedCrossRefGoogle Scholar
  40. 40.
    Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum 1992 Feb; 35(2): 129–37PubMedCrossRefGoogle Scholar
  41. 41.
    Sany J, Anaya JM, Lussiez V, et al. Treatment of rheumatoid arthritis with methotrexate: a prospective open long term study of 191 cases. J Rheumatol 1991 Sep; 18(9): 1323–7PubMedGoogle Scholar
  42. 42.
    Hanrahan PS, Scrivens GA, Russell AS. Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. Br J Rheumatol 1989 Apr; 28(2): 147–53PubMedCrossRefGoogle Scholar
  43. 43.
    Alarcon GS, Tracy IC, Blackburn Jr WD. Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum 1989 Jun; 32(6): 671–6PubMedCrossRefGoogle Scholar
  44. 44.
    Mielants H, Veys EM, Van der Straeten C, et al. The efficacy and toxicity of a constant low dose of methotrexate as a treatment for intractable rheumatoid arthritis: an open prospective study. J Rheumatol 1991 Jul; 18(7): 978–83PubMedGoogle Scholar
  45. 45.
    Rau R, Schleusser B, Herborn G, et al. Long-term treatment of destructive rheumatoid arthritis with methotrexate. J Rheumatol 1997 Oct; 24(10): 1881–9PubMedGoogle Scholar
  46. 46.
    Bologna C, Viu P, Picot MC, et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. Br J Rheumatol 1997 May; 36(5): 535–40PubMedCrossRefGoogle Scholar
  47. 47.
    Papadopoulos NG, Alamanos Y, Papadopoulos IA, et al. Disease modifying antirheumatic drugs in early rheumatoid arthritis: a long term observational study. J Rheumatol 2002 Feb; 29(2): 261–6PubMedGoogle Scholar
  48. 48.
    Drosos AA, Karantanas AH, Psychos D, et al. Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis? Clin Rheumatol 1990 Sep; 9(3): 342–5PubMedCrossRefGoogle Scholar
  49. 49.
    Drosos AA, Tsifetaki N, Tsiakou EK, et al. Influence of methotrexate on radiographic progression in rheumatoid arthritis: a sixty-month prospective study. Clin Exp Rheumatol 1997 May-Jun; 15(3): 263–7PubMedGoogle Scholar
  50. 50.
    Alarcon GS, Lopez-Mendez A, Walter J, et al. Radiographic evidence of disease progression in methotrexate treated and nonmethotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a meta-analysis. J Rheumatol 1992 Dec; 19(12): 1868–73PubMedGoogle Scholar
  51. 51.
    Bertino J. The mechanism of action of the folate antagonists in man. Cancer Res 1963; 29: 1286–308Google Scholar
  52. 52.
    Rau R. Methotrexate. In: Firestein GS, Panayi GS, Wallheim FA, editors. Rheumatoid arthritis: new frontiers in pathogenesis and treatment. Oxford (UK): Oxford University Press, 2000Google Scholar
  53. 53.
    Kremer JM, Alarcon GS, Weinblatt ME, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 1997 Oct; 40(10): 1829–37PubMedCrossRefGoogle Scholar
  54. 54.
    Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1985 Dec; 12Suppl. 12: 35–9Google Scholar
  55. 55.
    Phillips C, Cera PJ, Mangan TF, et al. Clinical liver disease in patients with rheumatoid arthritis taking methotrexate. J Rheumatol 1992 Feb; 19(2): 229–33PubMedGoogle Scholar
  56. 56.
    Seideman P, Muller-Suur R, Ekman E. Renal effects of low dose methotrexate in rheumatoid arthritis. J Rheumatol 1993 Jul; 20(7): 1126–8PubMedGoogle Scholar
  57. 57.
    Lang B, Riegel W, Peters T, et al. Low dose methotrexate therapy for rheumatoid arthritis conplicated by pancytopenia and Pneumocystis carinii pneumonia. J Rheumatol 1991 Aug; 18(8): 1257–9PubMedGoogle Scholar
  58. 58.
    Rustin GJ, Rustin F, Dent J, et al. No increase in second tumors after cytotoxic chemotherapy for gestational trophoblastic tumors. N Engl J Med 1983 Mar 3; 308(9): 473–6PubMedCrossRefGoogle Scholar
  59. 59.
    Georgescu L, Quinn GC, Schwartzman S, et al. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 1997 Jun; 26(6): 794–804PubMedCrossRefGoogle Scholar
  60. 60.
    Usman AR, Yunus MB. Non-Hodgkin’s lymphoma in patients with rheumatoid arthritis treated with low dose methotrexate. J Rheumatol 1996 Jun; 23(6): 1095–7PubMedGoogle Scholar
  61. 61.
    Voulgari PV, Vartholomatos G, Kaiafas P, et al. Rheumatoid arthritis and B-cell chronic lymphocytic leukemia. Clin Exp Rheumatol 2002 Jan-Feb; 20(1): 63–5PubMedGoogle Scholar
  62. 62.
    Morgan SL, Baggott JE, Vaughn WH, et al. The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 1990 Jan; 33(1): 9–18PubMedCrossRefGoogle Scholar
  63. 63.
    Weiblatt ME, Maier AL, Coblyn JS. Low dose leucovorin does not interfere with the efficacy of methotrexate in rheumatoid arthritis: an 8 week randomized placebo controlled trial. J Rheumatol 1993 Jun; 20(6): 950–2Google Scholar
  64. 64.
    Hanrahan PS, Russell AS. Concurrent use of folinic acid and methotrexate in rheumatoid arthritis. J Rheumatol 1988 Jul; 15(7): 1078–80PubMedGoogle Scholar
  65. 65.
    Joyce DA, Will RK, Hoffmann DM, et al. Exacerbation of rheumatoid arthritis in patients treated with methotrexate after administration of folinic acid. Ann Rheum Dis 1991 Dec; 50(12): 913–4PubMedCrossRefGoogle Scholar
  66. 66.
    Morgan SL, Baggott JE, Alarcon GS. Methotrexate in rheumatoid arthritis: folate supplementation should always be given. Biodrugs 1997; 8: 164–75PubMedCrossRefGoogle Scholar
  67. 67.
    Kremer JM, Alarcon GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994 Mar; 37(3): 316–28PubMedCrossRefGoogle Scholar
  68. 68.
    Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine compared with placebo in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1993 Dec 1; 119(11): 1067–71PubMedGoogle Scholar
  69. 69.
    Esdaile JM, Suissa S, Shiroky JM, et al. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA study. Am J Med 1995 Feb; 98(2): 156–68CrossRefGoogle Scholar
  70. 70.
    van der Heijde DM, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with “second-line” antirheumatic drugs: a randomized, controlled trial. Ann Intern Med 1996; 124: 699–707Google Scholar
  71. 71.
    American College of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. Arthritis Rheum 1996 May; 39(5): 723–31CrossRefGoogle Scholar
  72. 72.
    American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis 2002 update. Arthritis Rheum 2002 Feb; 46(2): 328–46CrossRefGoogle Scholar
  73. 73.
    Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. BMJ 1983 Oct 15; 287(6399): 1102–4PubMedCrossRefGoogle Scholar
  74. 74.
    Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988 Jun; 31(6): 702–13PubMedCrossRefGoogle Scholar
  75. 75.
    Dixon ASJ, Davies J, Dormandy TL, et al. Synthetic D(−) penicillamine in rheumatoid arthritis: double-blind controlled study of a high and low dosage regimen. Ann Rheum Dis 1975 Oct; 34(5): 416–21PubMedCrossRefGoogle Scholar
  76. 76.
    Cooperative Systemic Studies of Rheumatoid Disease Group. Toxicity of long term low dose D-penicillamine therapy in rheumatoid arthritis. J Rheumatol 1987 Feb; 14(1): 67–73Google Scholar
  77. 77.
    Empire Rheumatism Council Research Sub-committee. Gold therapy in rheumatoid arthritis: report of a multicenter, controlled trial. Ann Rheum Dis 1960; 19: 95–119CrossRefGoogle Scholar
  78. 78.
    American Rheumatism Association. The Cooperative Clinics Committee. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum 1973 May-Jun; 16(3): 353–8CrossRefGoogle Scholar
  79. 79.
    Sigler JW, Bluhim GB, Duncan H, et al. Gold salts in the treatment of rheumatoid arthritis: a double blind study. Ann Intern Med 1974; 80: 21–6PubMedGoogle Scholar
  80. 80.
    Sambrook PN, Browne CD, Champion GD, et al. Terminations of treatment with gold sodium thiomalate in rheumatoid arthritis. J Rheumatol 1982 Nov-Dec; 9(6): 932–4PubMedGoogle Scholar
  81. 81.
    Ward JR, Williams HJ, Egger MJ, et al. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis: a controlled clinical trial. Arthritis Rheum 1983 Nov; 26(11): 1303–15PubMedCrossRefGoogle Scholar
  82. 82.
    Urowitz MB, Gordon DA, Smythe HA, et al. Azathioprine in rheumatoid arthritis: a double-blind crossover study. Arthritis Rheum 1973 May-Jun; 16(3): 411–8PubMedCrossRefGoogle Scholar
  83. 83.
    Woodland S, Chaput de Saintouge DM, Evans SJ, et al. Azathioprine in rheumatoid arthritis: a double blind study of full versus half doses versus placebo. Ann Rheum Dis 1981; 40: 355–9PubMedCrossRefGoogle Scholar
  84. 84.
    Yocum DE, Torley H. Cyclosporin in rheumatoid arthritis. Rheum Dis Clin North Am 1995 Aug; 21(3): 835–44PubMedGoogle Scholar
  85. 85.
    Landewe RB, Goei The HS, van Rijthoven AW, et al. A randomized, double blind, 24-week controlled study of low-dose cyclosporin versus chloroquine for early rheumatoid arthritis. Arthritis Rheum 1994 May; 37(5): 637–43PubMedCrossRefGoogle Scholar
  86. 86.
    Forre O, Norwegian Arthritis Study Group. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporin: results of a 48-week multicenter study comparing low-dose cyclosporin with placebo. Arthritis Rheum 1994 Oct; 37(10): 1506–12PubMedCrossRefGoogle Scholar
  87. 87.
    Pasero G, Priolo F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthitis Rheum 1996 Jun; 39(6): 1006–15CrossRefGoogle Scholar
  88. 88.
    Drosos AA, Voulgari PV, Papadopoulos IA, et al. Cyclosporin A in the treatment of early rheumatoid arthritis: a prospective randomized 24-month study. Clin Exp Rheumatol 1998 Nov-Dec; 16(6): 695–701PubMedGoogle Scholar
  89. 89.
    Drosos AA, Voulgari PV, Katsaraki A, et al. Influence of cyclosporin A on radiological progression in early rheumatoid arthritis patients: a 42-month prospective study. Rheumatol Int 2000; 19(3): 113–8PubMedCrossRefGoogle Scholar
  90. 90.
    Kovarik JM, Koelle EU. Cyclosporin pharmacokinetics in the elderly. Drugs Aging 1999 Sep; 15(3): 197–205PubMedCrossRefGoogle Scholar
  91. 91.
    Landewe RB, Goei The HS, van Rijthoven AW, et al. Cyclosporin in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis. J Rheumatol 1994 Sep; 21(9): 1631–6PubMedGoogle Scholar
  92. 92.
    Torley H, Yocum D. Effects of dose treatment duration on adverse experience with cyclosporin in RA: analysis of North American Trials [abstract 1041]. Arthritis Rheum 1994; 37Suppl. S334: 334Google Scholar
  93. 93.
    Cash JM, Wilder RL. Refractory rheumatoid arthritis: therapeutic options. Rheum Dis Clin North Am 1995 Feb; 21(1): 1–18PubMedGoogle Scholar
  94. 94.
    Caldwell JR, Furst DE. The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis. Semin Arthritis Rheum 1991 Aug; 21(1): 1–11PubMedCrossRefGoogle Scholar
  95. 95.
    van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, et al. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double blind, placebo-controlled clinical trial. Ann Intern Med 2002 Jan 1; 136(1): 1–12PubMedGoogle Scholar
  96. 96.
    Lockie LM, Gomez E, Smith DM. Low dose adrenocorticosteroids in the management of elderly patients with rheumatoid arthritis: selected examples and summary of efficacy in the long-term management of 97 patients. Semin Arthritis Rheum 1983 May; 12(4): 373–81PubMedCrossRefGoogle Scholar
  97. 97.
    van Schaardenburg D, Valkema R, Dijkmans BA, et al. Prednisone treated of elderly-onset rheumatoid arthritis: disease activity and bone mass in comparison with chloroquine threatment. Arthritis Rheum 1995 Mar; 38(3): 334–42PubMedCrossRefGoogle Scholar
  98. 98.
    Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. J Rheumatol 1995 Jun; 22(6): 1055–9PubMedGoogle Scholar
  99. 99.
    American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996 Nov; 39(11): 1791–801CrossRefGoogle Scholar
  100. 100.
    Smith MD, Bertouch JV, Smith AM, et al. The clinical and immunological effects of pulse methylprednisolone therapy in rheumatoid arthritis: I. Clinical effects. J Rheumatol 1988 Feb; 15(2): 229–32PubMedGoogle Scholar
  101. 101.
    Mladenovic V, Domljan Z, Rozman B, et al. Safety and effectiveness of leflunomide in the treatment of patients with active rheumatoid arthritis: results of a randomized, placebo-controlled, phase II study. Arthritis Rheum 1995 Nov; 38(11): 1595–603PubMedCrossRefGoogle Scholar
  102. 102.
    Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999 Sep; 42(9): 1870–8PubMedCrossRefGoogle Scholar
  103. 103.
    Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelvemonth, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000 Mar; 43(3): 506–14PubMedCrossRefGoogle Scholar
  104. 104.
    Schiff MH, Goldmlum R, Rees MMC. New DMARD, mycophenolate mofetil, effectively treats refractory rheumatoid arthritis patients for one year [abstract]. Arthritis Rheum 1991; 34: S157Google Scholar
  105. 105.
    Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998 Sep; 41(9): 1552–63PubMedCrossRefGoogle Scholar
  106. 106.
    Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. ATTRACT Study Group. Lancet 1999 Dec 4; 354(9194): 1932–9PubMedCrossRefGoogle Scholar
  107. 107.
    Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: antitumor necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group. N Engl J Med 2000 Nov 30; 343(22): 1594–602PubMedCrossRefGoogle Scholar
  108. 108.
    Temekonidis TI, Georgiadis AN, Alamanos Y, et al. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. Ann Rheum Dis 2002 Sep; 61(9): 822–5PubMedCrossRefGoogle Scholar
  109. 109.
    Weinblatt ME, Kremer JM, Bankhurst AD. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340(4): 253–9PubMedCrossRefGoogle Scholar
  110. 110.
    Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337(3): 141–7PubMedCrossRefGoogle Scholar
  111. 111.
    Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000 Nov 30; 343(22): 1586–93PubMedCrossRefGoogle Scholar
  112. 112.
    Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001 Oct 11; 345(15): 1098–104PubMedCrossRefGoogle Scholar
  113. 113.
    Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab [letter]. Am J Med 2002 Nov; 113(7): 615PubMedCrossRefGoogle Scholar
  114. 114.
    Jobanputra P, Maggs F, Homer D, et al. Monitoring and assessing the safety of disease modifying antirheumatic drugs: a west Midland experience. Drug Saf 2002; 25: 1099–106PubMedCrossRefGoogle Scholar
  115. 115.
    Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998 Dec; 41(12): 2196–204PubMedCrossRefGoogle Scholar
  116. 116.
    Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000 May; 43(5): 1001–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Section of Rheumatology, Department of Internal Medicine, Medical SchoolUniversity of IoanninaIoanninaGreece

Personalised recommendations